287 filings
Page 3 of 15
8-K
qrsil3ai4tvaexn3i
2 Oct 20
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
naoc0d
24 Sep 20
JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study
10:45am
8-K
ooo96ah5s pkvnf
21 Sep 20
Regulation FD Disclosure
9:15am
8-K
xaz9rmi 1m1
16 Sep 20
JanOne Announces Strategic Plan to Divest its Legacy Businesses
4:29pm
8-K
85mi0dn
3 Sep 20
Other Events
1:30pm
8-K
fxps eqx6
26 Aug 20
JanOne Inc. (JAN) CEO Tony Isaac on Drug Candidate JAN101 - Telebriefing and Corporate Update Call Transcript
6:01am
8-K
a2fnp2i928
19 Aug 20
Regulation FD Disclosure
10:00am
8-K
bk7yc85ov99c3q5 u2
18 Aug 20
Regulation FD Disclosure
10:01am
8-K
cqq31lyudoqi
12 Aug 20
Regulation FD Disclosure
6:03am
8-K
iwz83
6 Aug 20
JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications
2:45pm
8-K
bdmc3eww
30 Jul 20
JanOne bolsters its scientific advisory board with two leaders in the medical field for vascular regeneration and interventional pain
9:42am
8-K
xsr71s
21 Jul 20
JanOne Receives FDA Authorization for Transfer of Investigational New Drug (IND) Application for its Sodium Nitrite Tablets
9:25am
8-K
duj6s481daz7p1nz
8 Jul 20
Other Events
9:31am
8-K
tl0ew
30 Jun 20
One of the nation’s most renowned pain experts, Dr. Edgar Ross, joins JanOne’s Scientific Advisory Board
9:31am
8-K
an0v8
25 Jun 20
Other Events
10:00am
8-K
atz0et7 24lu
18 Jun 20
JanOne Launches Strategic Alternatives Process for Legacy Businesses
9:38am
8-K
ifcqrxv1hrzfz60f
4 May 20
Entry into a Material Definitive Agreement
4:46pm
8-K/A
r57 5r0izpntzodm
23 Apr 20
Departure of Directors or Certain Officers
6:05am
8-K
beiq9nyrc49ldmdi5
22 Apr 20
Departure of Directors or Certain Officers
4:30pm
8-K
fun msxtj
7 Feb 20
JanOne strikes agreement with CoreRx, a leading cGMP contract manufacturer, for Phase 2b clinical formulation and development
12:00am